Capstone Holding

Capstone Holding EBITDA per Employee

The EBITDA per Employee of Capstone Holding (CAPS) as of Oct 27, 2026 is -38,526.88 USD. In the previous year, EBITDA per Employee was -6,860.22 USD — a change of 461.60% (lower).

EBITDA per Employee

-38,526.88USD

YoY

461.60%

Last updated:

EBITDA per Employee of Capstone Holding is 2025 -38,526.88 USD. EBITDA per Employee of Capstone Holding was 2024 -6,860.22 USD. It decreases by 461.60% lower compared to the previous year.

The Capstone Holding EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-4,268.82 USD
Jan 1, 2019
-7,774.19 USD
Jan 1, 2020
25,763.44 USD
Jan 1, 2021
49,849.46 USD
Jan 1, 2022
42,935.48 USD
Jan 1, 2023
-22,107.53 USD
Jan 1, 2024
-6,860.22 USD
Jan 1, 2025
-38,526.88 USD
The Capstone Holding EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-38,526.88USD+461.60%
-6,860.22USD-68.97%
-22,107.53USD-151.49%
42,935.48USD-13.87%
49,849.46USD+93.49%
25,763.44USD-431.40%
-7,774.19USD+82.12%
-4,268.82USD-76.37%
-18,064.52USD+6.06%
-17,032.26USD-46.10%
-31,602.15USD-35.04%
-48,645.16USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Capstone Holding Stock analysis

What does Capstone Holding do? Capstone Therapeutics Corp. is a biopharmaceutical company focused on the development of innovative therapeutic solutions for unmet medical needs. The company was founded in 1987 and is headquartered in Tempe, Arizona. It began as a research project at Arizona State University, eventually leading to the founding of the company. Capstone Therapeutics utilizes its technology platform in peptide chemistry, cell biology, and pharmacology to develop therapies for diseases with limited treatment options. Its core business includes developing medications for neurodegenerative diseases like Alzheimer's and oncological diseases with no effective treatment options. The company collaborates with other industry leaders in biotechnology and holds a strong intellectual property position. Capstone Therapeutics aims to improve the lives of individuals with serious illnesses through its innovative products and strategic approach. Capstone Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Capstone Holding stock

EBITDA per Employee of Capstone Holding is -38,526.88 USD in 2025.

EBITDA per Employee of Capstone Holding changed from -6,860.22 USD to -38,526.88 USD, representing a 461.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Capstone Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Capstone Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Capstone Holding

All Key Metrics — Capstone Holding